J. L. Bainbridge & Co., Inc. Biogen Inc. Transaction History
J. L. Bainbridge & Co., Inc.
- $1.13 Billion
- Q3 2025
A detailed history of J. L. Bainbridge & Co., Inc. transactions in Biogen Inc. stock. As of the latest transaction made, J. L. Bainbridge & Co., Inc. holds 2,969 shares of BIIB stock, worth $434,127. This represents 0.04% of its overall portfolio holdings.
Number of Shares
2,969
Previous 122,345
97.57%
Holding current value
$434,127
Previous $15.4 Million
97.3%
% of portfolio
0.04%
Previous 1.5%
Shares
7 transactions
Others Institutions Holding BIIB
# of Institutions
1,030Shares Held
131MCall Options Held
2.84MPut Options Held
2.54M-
Vanguard Group Inc Valley Forge, PA17.3MShares$2.53 Billion0.04% of portfolio
-
Primecap Management CO Pasadena, CA15.8MShares$2.31 Billion1.62% of portfolio
-
Black Rock Inc. New York, NY14.5MShares$2.13 Billion0.08% of portfolio
-
State Street Corp Boston, MA7.47MShares$1.09 Billion0.04% of portfolio
-
Wellington Management Group LLP Boston, MA4.8MShares$702 Million0.11% of portfolio
About BIOGEN INC.
- Ticker BIIB
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 144,000,992
- Market Cap $21.1B
- Description
- Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...